Clinical profile of patients with 30 days myocardial infarction and HS-CRP levels

Vamsi Krishna Kamana, Nawal Shabbar, M. Umesh Pai, Ravella Keerthika Chowdary

Research output: Contribution to journalArticle

Abstract

High sensitive- C Reactive Protein (Hs-CRP) evaluates vascular inflammation. Relatively high levels of Hs-CRP predicts of an increased risk of a future heart attack, stroke, sudden cardiac death, and/or peripheral arterial disease. In patients with Post myocardial infarction (MI) the role of serum CRP is not well known. The study was planned to analyze the clinical profile of patients with history of MI and raised Hs- CRP levels. This is a single centre, non-randomized, observational study, done on 155 post MI 30 days patients. Documentation of MI atleast 30 days prior to enrolment should be done by medical history of clinical symptoms consistent with myocardial ischemia, elevation of cardiac biomarkers or the development of pathological Q waves regardless of symptoms. Out of 155 subjects 131 were males and 24 females. The mean age was 56.03 yrs. Maximum had anterior wall MI, followed inferior wall MI and MI with bundle branch blocks. A total of 108 patients have normal LVEF i.e. EF > 50% and 47 patients are having LV dysfunction I.e., EF < 50%. The EF of 155 subjects was not statistically correlated with Hs-CRP levels (p 0.436). There are maximum numbers of subjects with DM and Hypertension with Hs-CRP levels < 1 mg/dl. Measurement of Hs-CRP during follow-up after 30 days of MI may be useful in evaluating the success and guiding the intensity of treatment with statins and other preventive interventions.

Original languageEnglish
Pages (from-to)878-884
Number of pages7
JournalResearch Journal of Pharmaceutical, Biological and Chemical Sciences
Volume7
Issue number5
Publication statusPublished - 01-09-2016

Fingerprint

C-Reactive Protein
Myocardial Infarction
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Biomarkers
Anterior Wall Myocardial Infarction
Inferior Wall Myocardial Infarction
Bundle-Branch Block
Peripheral Arterial Disease
Sudden Cardiac Death
Documentation
Observational Studies
Myocardial Ischemia
Blood Vessels
Stroke
Hypertension
Inflammation
Serum

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Kamana, Vamsi Krishna ; Shabbar, Nawal ; Umesh Pai, M. ; Chowdary, Ravella Keerthika. / Clinical profile of patients with 30 days myocardial infarction and HS-CRP levels. In: Research Journal of Pharmaceutical, Biological and Chemical Sciences. 2016 ; Vol. 7, No. 5. pp. 878-884.
@article{53d1eb80888e41bbbc1210e7a378bc43,
title = "Clinical profile of patients with 30 days myocardial infarction and HS-CRP levels",
abstract = "High sensitive- C Reactive Protein (Hs-CRP) evaluates vascular inflammation. Relatively high levels of Hs-CRP predicts of an increased risk of a future heart attack, stroke, sudden cardiac death, and/or peripheral arterial disease. In patients with Post myocardial infarction (MI) the role of serum CRP is not well known. The study was planned to analyze the clinical profile of patients with history of MI and raised Hs- CRP levels. This is a single centre, non-randomized, observational study, done on 155 post MI 30 days patients. Documentation of MI atleast 30 days prior to enrolment should be done by medical history of clinical symptoms consistent with myocardial ischemia, elevation of cardiac biomarkers or the development of pathological Q waves regardless of symptoms. Out of 155 subjects 131 were males and 24 females. The mean age was 56.03 yrs. Maximum had anterior wall MI, followed inferior wall MI and MI with bundle branch blocks. A total of 108 patients have normal LVEF i.e. EF > 50{\%} and 47 patients are having LV dysfunction I.e., EF < 50{\%}. The EF of 155 subjects was not statistically correlated with Hs-CRP levels (p 0.436). There are maximum numbers of subjects with DM and Hypertension with Hs-CRP levels < 1 mg/dl. Measurement of Hs-CRP during follow-up after 30 days of MI may be useful in evaluating the success and guiding the intensity of treatment with statins and other preventive interventions.",
author = "Kamana, {Vamsi Krishna} and Nawal Shabbar and {Umesh Pai}, M. and Chowdary, {Ravella Keerthika}",
year = "2016",
month = "9",
day = "1",
language = "English",
volume = "7",
pages = "878--884",
journal = "Research Journal of Pharmaceutical, Biological and Chemical Sciences",
issn = "0975-8585",
publisher = "RJPBCS",
number = "5",

}

Clinical profile of patients with 30 days myocardial infarction and HS-CRP levels. / Kamana, Vamsi Krishna; Shabbar, Nawal; Umesh Pai, M.; Chowdary, Ravella Keerthika.

In: Research Journal of Pharmaceutical, Biological and Chemical Sciences, Vol. 7, No. 5, 01.09.2016, p. 878-884.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical profile of patients with 30 days myocardial infarction and HS-CRP levels

AU - Kamana, Vamsi Krishna

AU - Shabbar, Nawal

AU - Umesh Pai, M.

AU - Chowdary, Ravella Keerthika

PY - 2016/9/1

Y1 - 2016/9/1

N2 - High sensitive- C Reactive Protein (Hs-CRP) evaluates vascular inflammation. Relatively high levels of Hs-CRP predicts of an increased risk of a future heart attack, stroke, sudden cardiac death, and/or peripheral arterial disease. In patients with Post myocardial infarction (MI) the role of serum CRP is not well known. The study was planned to analyze the clinical profile of patients with history of MI and raised Hs- CRP levels. This is a single centre, non-randomized, observational study, done on 155 post MI 30 days patients. Documentation of MI atleast 30 days prior to enrolment should be done by medical history of clinical symptoms consistent with myocardial ischemia, elevation of cardiac biomarkers or the development of pathological Q waves regardless of symptoms. Out of 155 subjects 131 were males and 24 females. The mean age was 56.03 yrs. Maximum had anterior wall MI, followed inferior wall MI and MI with bundle branch blocks. A total of 108 patients have normal LVEF i.e. EF > 50% and 47 patients are having LV dysfunction I.e., EF < 50%. The EF of 155 subjects was not statistically correlated with Hs-CRP levels (p 0.436). There are maximum numbers of subjects with DM and Hypertension with Hs-CRP levels < 1 mg/dl. Measurement of Hs-CRP during follow-up after 30 days of MI may be useful in evaluating the success and guiding the intensity of treatment with statins and other preventive interventions.

AB - High sensitive- C Reactive Protein (Hs-CRP) evaluates vascular inflammation. Relatively high levels of Hs-CRP predicts of an increased risk of a future heart attack, stroke, sudden cardiac death, and/or peripheral arterial disease. In patients with Post myocardial infarction (MI) the role of serum CRP is not well known. The study was planned to analyze the clinical profile of patients with history of MI and raised Hs- CRP levels. This is a single centre, non-randomized, observational study, done on 155 post MI 30 days patients. Documentation of MI atleast 30 days prior to enrolment should be done by medical history of clinical symptoms consistent with myocardial ischemia, elevation of cardiac biomarkers or the development of pathological Q waves regardless of symptoms. Out of 155 subjects 131 were males and 24 females. The mean age was 56.03 yrs. Maximum had anterior wall MI, followed inferior wall MI and MI with bundle branch blocks. A total of 108 patients have normal LVEF i.e. EF > 50% and 47 patients are having LV dysfunction I.e., EF < 50%. The EF of 155 subjects was not statistically correlated with Hs-CRP levels (p 0.436). There are maximum numbers of subjects with DM and Hypertension with Hs-CRP levels < 1 mg/dl. Measurement of Hs-CRP during follow-up after 30 days of MI may be useful in evaluating the success and guiding the intensity of treatment with statins and other preventive interventions.

UR - http://www.scopus.com/inward/record.url?scp=84987707850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987707850&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 878

EP - 884

JO - Research Journal of Pharmaceutical, Biological and Chemical Sciences

JF - Research Journal of Pharmaceutical, Biological and Chemical Sciences

SN - 0975-8585

IS - 5

ER -